Baird analyst Joel Beatty raised the firm’s price target on Axsome Therapeutics (AXSM) to $162 from $160 and keeps an Outperform rating on the shares. The firm updated its model following strong Q1 results and where the Symbravo launch is on track for June.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $165 from $160 at Wells Fargo
- Axsome Therapeutics: Strong Market Performance and Promising Growth Potential with Key Catalysts Ahead
- Axsome Therapeutics: Strong Growth Potential with Auvelity’s Market Expansion and Strategic Initiatives
- Axsome Therapeutics Reports Strong Q1 2025 Growth
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges